Augmenting Reference Pricing of Pharmaceuticals in New Zealand with Strategic Cross-Product Agreements
Year of publication: |
2001
|
---|---|
Authors: | Woodfield, Alan |
Published in: |
PharmacoEconomics. - Springer Healthcare | Adis, ISSN 1170-7690. - Vol. 19.2001, 4, p. 365-377
|
Publisher: |
Springer Healthcare | Adis |
Subject: | ACE inhibitors | Cost allocation | HMG CoA reductase inhibitors | Pharmacoeconomics | Reimbursement |
Extent: | application/pdf text/html |
---|---|
Type of publication: | Article |
Classification: | C - Mathematical and Quantitative Methods ; D - Microeconomics ; I - Health, Education, and Welfare ; Z - Other Special Topics ; I1 - Health ; I19 - Health. Other ; I18 - Government Policy; Regulation; Public Health ; I11 - Analysis of Health Care Markets |
Source: |
-
Pharmacoeconomic Considerations in Assessing and Selecting Congestive Heart Failure Therapies
Levy, Emile, (2002)
-
ACE Inhibitors after Myocardial Infarction: Clinical and Economic Considerations
Davie, Andrew P., (2000)
-
Cote, Isabelle, (2000)
- More ...
-
Optimal balanced-growth immigration policy for investors and entrepreneurs
Woodfield, Alan E., (1993)
-
Optimal long-run business immigration under differential savings functions
Woodfield, Alan E., (1993)
-
The welfare cost of taxation in New Zealand following major tax reforms
McKeown, Paul, (1993)
- More ...